LGVNLongeveron Inc.

$18M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-76.8% YoY

Gross Profit

$590,00045.2% margin

Operating Income

-$17M-1336.6% margin

Net Income

-$17M-1305.1% margin

EPS (Diluted)

$-9.00

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$11M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$43M

Total Liabilities

$5M

Stockholders' Equity

$37M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$6M	-76.8%
Gross Profit	$590,000	$2M	-67.7%
Operating Income	-$17M	-$4M	-362.0%
Net Income	-$17M	-$4M	-358.1%

LGVN FY 2021 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena